Rising list prices for drugs to treat multiple sclerosis corresponded with increased out-of-pocket costs for patients, according to a new study published by researchers at the University of Pittsburgh Medical Center in the Journal of the American Medical Association Neurology. The pattern persisted even after new drugs entered the market. The study findings challenge drug makers’ claims that list prices have little bearing on what most patients pay. Annual multiple sclerosis drug prices quadrupled from 2006 to 2016, while patient...